Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in Middle East From Hyperion Therapeutics, Inc.

Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in
Middle East From Hyperion Therapeutics, Inc.

STOCKHOLM, Sweden and SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 (GLOBE
NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Hyperion
Therapeutics, Inc., (Nasdaq:HPTX) announced today that Sobi has been granted
the exclusive rights by Hyperion to distribute RAVICTI (glycerol
phenylbutyrate) Oral Liquid on a named patient basis for the chronic treatment
of Urea Cycle Disorders (UCD) in the Middle East. Under the agreement, Sobi
receives the rights to provide RAVICTI in Saudi Arabia, Oman, United Arab
Emirates, Jordan, Kuwait, Qatar and Bahrain. Financial details were not

"We are proud of this partnership with Hyperion and RAVICTI is a perfect fit
with our existing UCD business and the capabilities within our Genetics
Therapeutic Area," said Geoffrey McDonough, President and CEO at Sobi. "We
believe the recent FDA approval of RAVICTI can allow us to provide access for
this important therapy in the Middle East."

UCD patients lack enzymes or transporters necessary for the conversion of
ammonia to urea and experience heightened levels of ammonia in the
bloodstream. Left untreated, UCDs can result in neurological damage, coma,
and/or death. Approved by the Food and Drug Administration on February 1,
2013, RAVICTI is an oral medication used for the long-term management of high
blood levels of ammonia.


In short term clinical studies involving more than 70 UCD patients ages two
years and older, RAVICTI was safe and efficacious based on 24-hour ammonia
profiles. In addition in long-term follow up studies, patients on RAVICTI
maintained average fasting ammonia levels below the upper limit of normal.

In the United States, RAVICTI is indicated for use as a nitrogen-binding agent
for chronic management of adult and pediatric patients ≥ 2 years of age with
UCDs who cannot be managed by dietary protein restriction and/or amino acid
supplementation alone. RAVICTI must be used with dietary protein restriction
and, in some cases, dietary supplements (e.g., essential amino acids,
arginine, citrulline, protein-free calorie supplements).RAVICTI is not
indicated for the treatment of acute hyperammonemia in patients with UCDs
because more rapidly acting interventions are essential to reduce plasma
ammonia levels.The safety and efficacy of RAVICTI for the treatment of
N-acetylglutamate synthase (NAGS) deficiency has not been established.The use
of RAVICTI in patients < 2 months of age is contraindicated.

For additional Important Safety Information, including Warnings and
Precautions, Adverse Events, Drug Interactions, and Special Populations,
please see full Prescribing Information (PDF) and Medication Guide (PDF) for

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi
is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of
SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO:SOBI) is
listed on NASDAQ OMX Stockholm. More information is available at

About Hyperion Therapeutics, Inc.

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, RAVICTI®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide.For
more information, please visit

         Media relations
         Oskar Bosson
         Head of Communications
         T: +46 70 410 71 80
         Investor relations
         Jorgen Winroth
         Vice President, Head of Investor Relations
         T: +46 8 697 20 00
         Hyperion Therapeutics, Inc.
         Sylvia Wheeler
         Vice President, Investor Relations
         T: (650) 745-7834
Press spacebar to pause and continue. Press esc to stop.